CN109096400A - Anti- PDPN protein monoclonal antibody and application thereof - Google Patents
Anti- PDPN protein monoclonal antibody and application thereof Download PDFInfo
- Publication number
- CN109096400A CN109096400A CN201811015868.3A CN201811015868A CN109096400A CN 109096400 A CN109096400 A CN 109096400A CN 201811015868 A CN201811015868 A CN 201811015868A CN 109096400 A CN109096400 A CN 109096400A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- pdpn
- oti3h5
- application
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to field of biotechnology, disclose a kind of hybridoma cell strain (deposit number is CGMCC No.15592), and the monoclonal antibody OTI3H5 that thus hybridoma cell strain generates.The invention further relates to monoclonal antibody OTI3H5 to prepare the application in the immune detection tool for detecting PDPN albumen, application of the immunohistochemical kit and monoclonal antibody OTI3H5 of the OTI3H5 containing monoclonal antibody in the kit that preparation is used for marked tumor.Monoclonal antibody of the present invention can in conjunction with PDPN protein-specific, and with other intracellular albumen no cross reactions, significantly improve specificity, the accuracy and reliability of the detection of PDPN protein immunization.
Description
Technical field
The present invention relates to oncology and medical domain, and in particular to can specific bond PDPN albumen monoclonal antibody
The method and purposes of OTI3H5, the cell strain for generating the monoclonal antibody and the application antibody for tumour Identification of The Origin.
Background technique
Flatfoot albumen (podoplanin, PDPN) discovery expression earliest is the specificity mark of lymphatic endothelial in lymphatic vessel
Will object, in the surface wide expression of the various tumour cells of the mankind, express to and tumour grade malignancy and prognosis it is related.
The current expression situation for clinically commonly using albumen in immunohistochemistry (IHC) Pathological experiment detection tumour cell, however IHC
The core of experiment be binding proteins specific monoclonal antibody, the superiority and inferiority of performance directly decide entirely detect it is sensitive
Degree and specificity.Therefore, a kind of higher monoclonal antibody for PDPN albumen of binding specificity is developed to detect IHC
PDPN expression has great importance.
Summary of the invention
In view of this, the purpose of the present invention is to provide a kind of monoclonals of the higher PDPN albumen of binding specificity to resist
Body, and its preparing the application in the immune detection tool for detecting PDPN albumen.
The present invention provides a kind of hybridoma cell strains, and it is common to be preserved in China Committee for Culture Collection of Microorganisms
Microorganism center (referred to as CGMCC), the deposit date is on April 26th, 2018, deposit number was CGMCC No.15592.
The present invention also provides a kind of monoclonal antibody OTI3H5 for specifically binding PDPN albumen, by above-mentioned hybridoma
Cell strain generates.
Monoclonal antibody of the present invention the preparation method is as follows:
(1) building of recombinant expression carrier: according to PDPN ORF nucleotide sequence (PDPN ORF nucleotide sequence such as SEQ
Shown in ID NO.1,714bp；PDPN amino acid sequence is as shown in SEQ ID NO.2)
Design primer PCR amplification PDPN ORF 67bp to 393bp bit sequence, gene two sides introduce limitation respectively
Property restriction enzyme site SgfI and MluI, be inserted into expression vector pET23a-N-His, building PDPN amino acid sequence the 23rd to the
131 recombinant expression plasmid pET23a-rPDPN；Upstream amplification primer sequence, SEQ ID NO.3:CACGCGATCGCG
GCTCGGGCACCCTCCCT downstream amplification primer sequence SEQ ID NO.4:ACCGACGCGT CTA
GGTTCCTGGAGTCACCAC
(2) expression and purification of PDPN recombinant protein: by PDPN recombinant expression plasmid Transformed E .Coli cell, crack from
The heart obtains supernatant, and affinity chromatography column purification obtains the PDPN recombinant protein of purifying；
(3) screening and preparation of monoclonal antibody: being immunized Balb/c mouse using the PDPN recombinant protein of above-mentioned purifying,
Mouse spleen cells are taken to be merged with SP2/0 cell, limiting dilution assay obtains monoclonal, and ELISA method screens positive hybridoma
Cell obtains the hybridoma cell strain that can secrete anti-PDPN specific antibody, is named as OTI3H5, subtype identification IgG2a；
Antibody is prepared by serum free medium, PDPN monoclonal antibody OTI3H5 is obtained by affinity chromatography column purification.Pass through respectively
Western Blot, immunohistochemical experiment verify the sensitivity and specificity of the monoclonal antibody.
The present invention also provides monoclonal antibody OTI3H5 in preparing the immune detection tool for detecting PDPN albumen
Application.
Specifically, the immune detection tool is kit, chip or test paper.
In the particular embodiment, the present invention provides a kind of immunologic combined detection reagent kit, including above-mentioned monoclonal are anti-
Body OTI3H5 can detect the expression situation of PDPN in histocyte.
The present invention also provides application of the said monoclonal antibody in the kit that preparation is used for marked tumor.Wherein
The tumour specifically refers to the tumour of tumour cell being proliferated and the expression of PDPN is closely related, including but not limited to lymthoma
Tissue.
Compared with prior art, the present invention provides a kind of hybridoma cell strain (deposit number CGMCC
No.15592), and the thus monoclonal antibody OTI3H5 that hybridoma cell strain generates.It is anti-that the present invention also provides monoclonals
Body OTI3H5 is preparing the application in the immune detection tool for detecting PDPN albumen, and the OTI3H5's containing monoclonal antibody exempts from
The application of epidemic disease group kit and monoclonal antibody OTI3H5 in the kit that preparation is used for marked tumor.Institute of the present invention
Stating monoclonal antibody can be true to reflect PDPN protein expression level in tumour cell in conjunction with PDPN protein-specific, can apply
In dividing tissue lymphatic endothelial and blood vessel endothelium.
Preservation information
The classification naming of hybridoma cell strain OTI3H5 for preservation are as follows: the hybridoma of PDPN mouse monoclonal antibody is thin
Born of the same parents' strain；
Depositary institution's full name: China Committee for Culture Collection of Microorganisms's common micro-organisms center；
Depositary institution's abbreviation: CGMCC；
Depositary institution address: Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3 Institute of Microorganism, Academia Sinica；
Preservation date: on April 26th, 2018；
Deposit number: CGMCC No.15592.
Detailed description of the invention
In order to more clearly explain the embodiment of the invention or the technical proposal in the existing technology, below will to embodiment or
Attached drawing needed to be used in the description of the prior art is briefly described.
Fig. 1 shows the design of 1 cloning site of embodiment as schemed, and wherein shading part is the area ORF；
Fig. 2-4 shows that 4 formalin of embodiment is fixed, the normal lung of paraffin embedding, lymthoma, normal tonsil are exempted from
Epidemic disease group result figure (primary antibody is PDPN monoclonal antibody OTI3H5)；
Specific embodiment
Below in conjunction with the embodiment of the present invention, technical solution in the embodiment of the present invention is clearly and completely retouched
It states, it is clear that described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.Based on the present invention
In embodiment, every other implementation obtained by those of ordinary skill in the art without making creative efforts
Example, shall fall within the protection scope of the present invention.
The building of embodiment 1, PDPN recombinant expression plasmid
With the plasmid RC224811 (714bp of ORF containing PDPN) obtained from Biotechnology Co., Ltd of Aureal Dongyuan County of the U.S.
For template, designs two primers and introduces restriction enzyme site SgfI and MluI respectively, be cloned into expression vector pET23a-N-His,
Establish PDPN recombinant expression plasmid.Cloning site design is as shown in Figure 1.
The expression and purification of embodiment 2, PDPN recombinant protein
1, Transformed E .coli cell: being added Plasmid DNA and gently mix after 100ul competent cell is placed on ice to melt, ice
42 DEG C of heat shock 90s after bath 30min, are then continued ice bath 1-2min.The fresh nonreactive LB training of 500ul is added in super-clean bench
Base is supported, takes appropriate bacterium solution to be spread evenly across on antibiotic plate after 37 DEG C of shaking tables are incubated for 45min, culture dish is inverted
The overnight incubation in 37 DEG C of constant incubators.
2, lytic cell: picking monoclonal in fresh culture, 37 DEG C, 200rpm cultivate to OD value reach 0.4~
IPTG (final concentration 1mM) Fiber differentiation 7h is added when 0.6.Thalline were collected by centrifugation, and thallus then is resuspended with lysis buffer, surpasses
Sound is crushed after 20min the 12000rpm at 4 DEG C and is centrifuged 20min, collection supernatant.Take a small amount of supernatant protein anti-His antibody
Do WB identification.
3, affinity chromatography column purification: nickel column is balanced with buffer, simultaneously by loading after 0.45 μm of membrane filtration of supernatant
Collection outflow, the albumen being not associated with buffer elution removal, finally with the elution of the imidazoles containing various concentration, difference
SDS-PAGE identification is carried out after collection, satisfactory elution albumen is merged, 10% glycerol is added, recombination PDPN after purification
Albumen is identified with SDS-PAGE.
The preparation and screening of embodiment 3, PDPN monoclonal antibody
The PDPN protein fragments of the purifying generated according to standard method recombination are used to (tie up logical in Beijing to Balb/c mouse
Li Hua experimental animal Technology Co., Ltd.) it is immunized.The specific method is as follows:
1, animal immune: purified PDPN antigen is emulsified with complete Freund's adjuvant, using subcutaneous or intraperitoneal injection side
6-8 week old Balb/c mouse is immunized in method, and immunizing dose is 50 μ g/, and progress is immune for the second time after two weeks at interval, with incomplete
Freund's adjuvant emulsification, immunizing dose are 50 μ g/.It is immune to take tail blood with ELISA method gradient dilution measurement serum effect afterwards twice
Valence；Booster immunization is determined whether according to result, is chosen the highest mouse of antibody titer and is carried out cell fusion.
2, cell fusion: myeloma cell uses the sp2/0 in the source Balb/c, and logarithmic growth phase is in when fusion；It takes
Immune mouse spleen, is made lymphocyte single cell suspension；Mouse spleen lymphocyte and myeloma cell are mixed with 1:5-1:10
37 DEG C 50%PEG (PH 8.0) 1mL is added dropwise in conjunction, and incomplete culture medium and remaining terminate liquid is added, and centrifugation adds after abandoning supernatant
Enter the suspension of HAT culture medium to mix, MC constant volume to 50mL is dispensed into 3.5cm culture dish, is put in wet box, is placed in 37 DEG C, 5%
CO2It is cultivated in constant incubator.
3, screen and clone: fusion selected cell clone in 7-10 days, carried out ELISA using PDPN purification of recombinant proteins
Test.Mark cell strain number.Limiting dilution is carried out to positive hole cell, 5-6 days measurement ELISA values after each limiting dilution are chosen
The higher monoclonal hole of OD280 positive value is taken to carry out limiting dilution, hardened fruit is the positive entirely until ELISA measures 96 orifice plates.It chooses
The monoclonal singling for taking positive value high.It is OTI3H5 that it, which corresponds to fusion plate cell strain,.
4, the preparation and purification of ascites monoclonal antibodies: the male Balb/c mouse peritoneal of 10-12 week old injects 0.5ml norphytane,
Every mouse is injected intraperitoneally with 1mL syringe and wash the monoclonal cell suspension being resuspended through PBS after a week, cell dosage for 5 ×
106/ only, every strain antibody makes a call to 2 mouse.Ascites, centrifuging and taking supernatant are collected after mouse ascites accumulation, affinity chromatography carries out
Ascites purifying selects corresponding column material according to antibody subtype, and the monoclonal antibody that cell strain OTI3H5 is generated is IgG2a, using protein
G is purified.Monoclonal antibody concentration mensuration after purification, WB are detected, dispense, are frozen at -20 DEG C.
Embodiment 4, the immunohistochemistry that monoclonal antibody OTI3H5 is primary antibody detect
(1), experimental method:
1, the people's lymph node tissue and human tonsil's tissue block for taking formalin fixed carry out paraffin embedding, use
Finesse histotome is sliced, and tissue thickness is 6 μm.
2, dewaxing and aquation: analyzing pure 3 × 10min of dimethylbenzene, dehydrated alcohol 3 × 10min, 95% ethyl alcohol 5min, and 85%
Ethyl alcohol 5min, 75% ethyl alcohol 5min, deionized water impregnate 3min × 3 time
3, antigen retrieval buffers (0.01M, pH6.0 sodium citrate buffer) pressure cooker hot high pressure is added and repairs 3min, to height
When pressure pot temperature is down to about 90 DEG C, pressure cooker is opened, takes out sample, then cooled to room temperature.Deionized water impregnates 3min
× 3 times.
4, using 3% hydrogen peroxide deactivation tissue endogenous peroxydase, it is stored at room temperature 10min.Deionized water is impregnated
5min × 3 time.
5, confining liquid (+5% Normal Goat Serum of PBS+5% skimmed milk power) is added, 37 DEG C of incubation 60min.
6, confining liquid is removed, is not rinsed, is added PDPN monoclonal antibody (OTI3H5), thinner ratio: 1:150 is carried out using confining liquid
Dilution.It is placed in wet box, 37 DEG C of incubation 60min.PBST (0.1%Tween-20) is washed 2 times, washs 5min every time.PBST
(0.02%Tween-20) is washed 1 time, washs 5min every time.
7,1,37 DEG C of reagent of Polink- kit 2 (Catlog No.D37-15) incubation 10-20 minutes is added dropwise.It uses
PBS is washed 3 times, each 5min.2,37 DEG C of incubation 10-20 of Polink-2 kit (Catlog No.D37-15) reagent are added dropwise
Minute, it is washed 3 times using PBS, each 5min.
8, it develops the color using DAB solution (Zhong Shan Golden Bridge ZLI-9019), develop the color 3~10min.Distill water washing.
9, haematoxylin redyeing nucleus 2min, distilled water rinsing, the differentiation of 1% hydrochloric acid.Distilled water rinses 3 times, is stored at room temperature
1min。
10, it is dehydrated and transparent: 75% ethyl alcohol 5min, 100% ethyl alcohol 5min x 3 times, 85% ethyl alcohol 5min, 95% ethyl alcohol
5min, 100% 3 × 5min of ethyl alcohol；3 × 5min of dimethylbenzene, neutral gum mounting.
11, microscopy is shown in Fig. 2-4.
(2), experimental result:
By the result of Fig. 2~4 as it can be seen that in the lymphatic endothelial of normal lung, tonsillotome and lymthoma visible specificity
Dyeing, and to blood vessel endothelium without intersection.As a result consistent with PDPN positioning in the cell and tissue expression specificity, show list
Clonal antibody OTI3H5 can be used for the level of Immunohistochemical detection PDPN albumen.
<110>Wuxi Origene Bio-tech Co., Ltd.
<120>anti-PDPN protein monoclonal antibody and application thereof
<210> 1
<211>2961
<212> DNA
<213>artificial sequence
<400> 1
ORIGIN
1 ATGCTGACTC CGCTCGGAAA GTTCTCAACT GCAAAGTTTG CTGTCCGGCT GCCTAGGGTC
61 TGGGAAGCTC GGGCACCCTC CCTCTCCGGG GCTCCTGCTC CCACCCCTCC GGCCCCCCCA
121 CCGTCGCGCT CCTCCAGGCT GGGCCTGTGG CCGCGGTGCT TTTTAATTTT CCCCCAGCTC
181 AGAATCTTGC TGCTCGGCCC CCAGGAGAGC AACAACTCAA CGGGAACGAT GTGGAAGGTG
241 TCAGCTCTGC TCTTCGTTTT GGGAAGCGCG TCGCTCTGGG TCCTGGCAGA AGGAGCCAGC
301 ACAGGCCAGC CAGAAGATGA CACTGAGACT ACAGGTTTGG AAGGCGGCGT TGCCATGCCA
361 GGTGCCGAAG ATGATGTGGT GACTCCAGGA ACCAGCGAAG ACCGCTATAA GTCTGGCTTG
421 ACAACTCTGG TGGCAACAAG TGTCAACAGT GTAACAGGCA TTCGCATCGA GGATCTGCCA
481 ACTTCAGAAA GCACAGTCCA CGCGCAAGAA CAAAGTCCAA GCGCCACAGC CTCAAACGTG
541 GCCACCAGTC ACTCCACGGA GAAAGTGGAT GGAGACACAC AGACAACAGT TGAGAAAGAT
601 GGTTTGTCAA CAGTGACCCT GGTTGGAATC ATAGTTGGGG TCTTACTAGC CATCGGCTTC
661 ATTGGTGGAA TCATCGTTGT GGTTATGCGA AAAATGTCGG GAAGGTACTC GCCC
//
<210> 2
<211>986
<212> PRT
<213>artificial sequence
<400> 2
ORIGIN
1 MLTPLGKFST AKFAVRLPRV WEARAPSLSG APAPTPPAPP PSRSSRLGLW PRCFLIFPQL
61 RILLLGPQES NNSTGTMWKV SALLFVLGSA SLWVLAEGAS TGQPEDDTET TGLEGGVAMP
121 GAEDDVVTPG TSEDRYKSGL TTLVATSVNS VTGIRIEDLP TSESTVHAQE QSPSATASNV
181 ATSHSTEKVD GDTQTTVEKD GLSTVTLVGI IVGVLLAIGF IGAIIVVVMR KMSGRYSP
Claims (6)
1. a kind of monoclonal antibody, which is characterized in that it specifically binds with flatfoot albumen (podoplanin, PDPN)；
The monoclonal antibody is generated by hybridoma cell strain OTI3H5, and deposit number is CGMCC No.15592.
2. monoclonal antibody as described in claim 1 is in preparation for the immune of dividing tissue lymphatic endothelial and blood vessel endothelium
Application in detection instrument.
3. application according to claim 2, the immune detection tool is reagent, kit, chip or test paper.
4. a kind of immunologic combined detection reagent kit, which is characterized in that including monoclonal antibody described in claim 1.
5. application of the monoclonal antibody as described in claim 1 in the kit that preparation is used for tagged tissue cell.
6. application according to claim 5, the histocyte is that the tumour of vascular source property and Testicular Germ Cell swell
Tumor tissue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811015868.3A CN109096400A (en) | 2018-09-01 | 2018-09-01 | Anti- PDPN protein monoclonal antibody and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811015868.3A CN109096400A (en) | 2018-09-01 | 2018-09-01 | Anti- PDPN protein monoclonal antibody and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109096400A true CN109096400A (en) | 2018-12-28 |
Family
ID=64864757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811015868.3A Pending CN109096400A (en) | 2018-09-01 | 2018-09-01 | Anti- PDPN protein monoclonal antibody and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109096400A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114214411A (en) * | 2021-12-27 | 2022-03-22 | 上海解颐生物科技有限公司 | circRNA marker for glioma diagnosis and glioma diagnosis kit |
| CN115786515A (en) * | 2022-11-25 | 2023-03-14 | 徐州医科大学 | Application of PDPN in diagnosis and treatment of Lapatinib drug-resistant HER2 positive gastric cancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106947744A (en) * | 2017-03-14 | 2017-07-14 | 福州迈新生物技术开发有限公司 | The hybridoma cell strain of one plant of anti-flatfoot protein monoclonal antibody of secretion and its application |
-
2018
- 2018-09-01 CN CN201811015868.3A patent/CN109096400A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106947744A (en) * | 2017-03-14 | 2017-07-14 | 福州迈新生物技术开发有限公司 | The hybridoma cell strain of one plant of anti-flatfoot protein monoclonal antibody of secretion and its application |
Non-Patent Citations (1)
| Title |
|---|
| UNIPROT数据库: "Q86YL7", 《UNIPROT》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114214411A (en) * | 2021-12-27 | 2022-03-22 | 上海解颐生物科技有限公司 | circRNA marker for glioma diagnosis and glioma diagnosis kit |
| CN114214411B (en) * | 2021-12-27 | 2022-12-13 | 上海解颐生物科技有限公司 | circRNA marker for glioma diagnosis and glioma diagnosis kit |
| CN115786515A (en) * | 2022-11-25 | 2023-03-14 | 徐州医科大学 | Application of PDPN in diagnosis and treatment of Lapatinib drug-resistant HER2 positive gastric cancer |
| CN115786515B (en) * | 2022-11-25 | 2023-09-12 | 徐州医科大学 | Application of PDPN in HER2 positive gastric cancer diagnosis and treatment of lapatinib resistance |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106978400A (en) | Anti- PD L1 protein monoclonal antibodies and application thereof | |
| CN108997496A (en) | Anti- GFAP protein monoclonal antibody and application thereof | |
| CN107188962A (en) | Anti- CK7 protein monoclonal antibodies and application thereof | |
| CN108467432A (en) | The monoclonal antibody and its cell strain, preparation method and application of anti-E-cadherin albumen | |
| CN105131114B (en) | The anti-p16 monoclonal antibodies and application of anti-p16 protein monoclonal antibodies hybridoma and its generation | |
| CN106188292B (en) | Anti- CD4 protein monoclonal antibody and application thereof | |
| CN105238762A (en) | Anti-PD-1 protein monoclonal antibody hybridomas cell, anti- PD-1 monoclonal antibody generated by same and application | |
| CN109096400A (en) | Anti- PDPN protein monoclonal antibody and application thereof | |
| JP2000509269A (en) | Hepatitis B monoclonal antibody | |
| CN102827281B (en) | Monoclonal antibody against CD2 protein and application thereof | |
| CN108997501A (en) | Anti- VWF protein monoclonal antibody and application thereof | |
| CN105254759A (en) | Anti-CD56 protein monoclonal antibody hybridoma cell, anti-CD56 monoclonal antibody generated by same and application | |
| CN107188965A (en) | Anti- DOG1 protein monoclonal antibodies and application thereof | |
| Sander et al. | Monoclonal antibodies against plant viruses | |
| CN102227445B (en) | Antibody capable of binding to envelope protein 2 of hepatitis c virus, and method for identifying genotype of hepatitis c virus using same | |
| CN110357964A (en) | 1 protein monoclonal antibody of AntiCD3 McAb and application thereof | |
| CN109021102A (en) | Anti- SMA protein monoclonal antibody and application thereof | |
| CN107446046A (en) | Anti- CD20 protein monoclonal antibodies and application thereof | |
| CN106957823A (en) | Anti- PD L2 protein monoclonal antibodies and application thereof | |
| CN106977605A (en) | Anti- CD19 protein monoclonal antibodies and application thereof | |
| CN109021101A (en) | Anti- PAX8 protein monoclonal antibody and application thereof | |
| CN106749668A (en) | Anti- IDO1 protein monoclonal antibodies and application thereof | |
| CN106854245A (en) | Protein monoclonal antibody of AntiCD3 McAb 0 and application thereof | |
| CN108998423A (en) | Anti- vimentin (Vimentin) monoclonal antibody and application thereof | |
| CN105175543A (en) | E-Cadherin protein resisting monoclonal antibody hybridoma, E-Cadherin resisting monoclonal antibody generated by same and application of E-Cadherin resisting monoclonal antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181228 |